Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

47.41
Delayed Data
As of Aug 16
 +0.88 / +1.89%
Today’s Change
24.58
Today|||52-Week Range
60.01
-0.88%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$5.8B

Company Description

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates its business through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke on January 10, 1989 and is headquartered in Carlsbad, CA.

Contact Information

Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad California 92010
P:(760) 931-9200
Investor Relations:
(760) 603-2331

Employees

Shareholders

Mutual fund holders56.35%
Other institutional34.91%
Individual stakeholders0.83%

Top Executives

Stanley T. CrookeChairman, President & Chief Executive Officer
B. Lynne ParshallChief Operating Officer & Inside Director
Elizabeth L. HougenCFO, Principal Accounting Officer & SVP-Finance
Patrick R. O'NeilSecretary, Chief Compliance Officer & SVP-Legal
C. Frank BennettSenior Vice President-Antisense Research